Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 45,100 shares, a growth of 16.2% from the September 30th total of 38,800 shares. Based on an average trading volume of 182,400 shares, the short-interest ratio is currently 0.2 days.

Astellas Pharma Stock Down 0.6 %

OTCMKTS:ALPMY opened at $11.28 on Tuesday. The company has a current ratio of 0.90, a quick ratio of 0.72 and a debt-to-equity ratio of 0.26. Astellas Pharma has a twelve month low of $9.15 and a twelve month high of $13.14. The company has a market cap of $20.40 billion, a PE ratio of 161.07 and a beta of 0.37. The company’s 50 day moving average is $11.97 and its two-hundred day moving average is $10.79.

Astellas Pharma (OTCMKTS:ALPMY) last released its earnings results on Thursday, August 1st. The company reported $0.24 earnings per share (EPS) for the quarter. Astellas Pharma had a return on equity of 7.79% and a net margin of 1.17%. The firm had revenue of $3.03 billion for the quarter. Analysts anticipate that Astellas Pharma will post 0.54 EPS for the current year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.